Cervera-Carrascon V - Search Results

1

An oncolytic adenovirus coding for a variant interleukin 2 cytokine improves response to chemotherapy through enhancement of effector lymphocyte cytotoxicity, fibroblast compartment modulation and mitotic slippage.

Pakola S, Quixabeira DCA, Kudling TV, Clubb JHA, Grönberg-Vähä-Koskela S, Basnet S, Jirovec E, Arias V, Haybout L, Heiniö C, Santos JM, Cervera-Carrascon V, Havunen R, Anttila M, Hemminki A. Pakola S, et al. Among authors: cervera carrascon v. Front Immunol. 2023 Jul 5;14:1171083. doi: 10.3389/fimmu.2023.1171083. eCollection 2023. Front Immunol. 2023. PMID: 37475863 Free PMC article.

2

Adenoviral Delivery of Tumor Necrosis Factor-α and Interleukin-2 Enables Successful Adoptive Cell Therapy of Immunosuppressive Melanoma.

Siurala M, Havunen R, Saha D, Lumen D, Airaksinen AJ, Tähtinen S, Cervera-Carrascon V, Bramante S, Parviainen S, Vähä-Koskela M, Kanerva A, Hemminki A. Siurala M, et al. Mol Ther. 2016 Aug;24(8):1435-43. doi: 10.1038/mt.2016.137. Epub 2016 Jun 30. Mol Ther. 2016. PMID: 27357626 Free PMC article.

3

Adenoviral production of interleukin-2 at the tumor site removes the need for systemic postconditioning in adoptive cell therapy.

Santos JM, Havunen R, Siurala M, Cervera-Carrascon V, Tähtinen S, Sorsa S, Anttila M, Karell P, Kanerva A, Hemminki A. Santos JM, et al. Int J Cancer. 2017 Oct 1;141(7):1458-1468. doi: 10.1002/ijc.30839. Epub 2017 Jun 29. Int J Cancer. 2017. PMID: 28614908

4

TNFa and IL-2 armed adenoviruses enable complete responses by anti-PD-1 checkpoint blockade.

Cervera-Carrascon V, Siurala M, Santos JM, Havunen R, Tähtinen S, Karell P, Sorsa S, Kanerva A, Hemminki A. Cervera-Carrascon V, et al. Oncoimmunology. 2018 Apr 9;7(5):e1412902. doi: 10.1080/2162402X.2017.1412902. eCollection 2018. Oncoimmunology. 2018. PMID: 29721366 Free PMC article.

5

Adenovirus Coding for Interleukin-2 and Tumor Necrosis Factor Alpha Replaces Lymphodepleting Chemotherapy in Adoptive T Cell Therapy.

Santos JM, Cervera-Carrascon V, Havunen R, Zafar S, Siurala M, Sorsa S, Anttila M, Kanerva A, Hemminki A. Santos JM, et al. Mol Ther. 2018 Sep 5;26(9):2243-2254. doi: 10.1016/j.ymthe.2018.06.001. Epub 2018 Jul 13. Mol Ther. 2018. PMID: 30017877 Free PMC article.

6

CD40L coding oncolytic adenovirus allows long-term survival of humanized mice receiving dendritic cell therapy.

Zafar S, Sorsa S, Siurala M, Hemminki O, Havunen R, Cervera-Carrascon V, Santos JM, Wang H, Lieber A, De Gruijl T, Kanerva A, Hemminki A. Zafar S, et al. Oncoimmunology. 2018 Aug 15;7(10):e1490856. doi: 10.1080/2162402X.2018.1490856. eCollection 2018. Oncoimmunology. 2018. PMID: 30386680 Free PMC article.

7

Abscopal Effect in Non-injected Tumors Achieved with Cytokine-Armed Oncolytic Adenovirus.

Havunen R, Santos JM, Sorsa S, Rantapero T, Lumen D, Siurala M, Airaksinen AJ, Cervera-Carrascon V, Tähtinen S, Kanerva A, Hemminki A. Havunen R, et al. Mol Ther Oncolytics. 2018 Nov 6;11:109-121. doi: 10.1016/j.omto.2018.10.005. eCollection 2018 Dec 21. Mol Ther Oncolytics. 2018. PMID: 30569015 Free PMC article.

8

Effect of Genetic Modifications on Physical and Functional Titers of Adenoviral Cancer Gene Therapy Constructs.

Heiniö C, Sorsa S, Siurala M, Grönberg-Vähä-Koskela S, Havunen R, Haavisto E, Koski A, Hemminki O, Zafar S, Cervera-Carrascon V, Munaro E, Kanerva A, Hemminki A. Heiniö C, et al. Hum Gene Ther. 2019 Jun;30(6):740-752. doi: 10.1089/hum.2018.240. Epub 2019 Feb 28. Hum Gene Ther. 2019. PMID: 30672366

9

Oncolytic adenoviruses: a game changer approach in the battle between cancer and the immune system.

Cervera-Carrascon V, Havunen R, Hemminki A. Cervera-Carrascon V, et al. Expert Opin Biol Ther. 2019 May;19(5):443-455. doi: 10.1080/14712598.2019.1595582. Epub 2019 Mar 25. Expert Opin Biol Ther. 2019. PMID: 30905206 Review.

10

Constitutively active GSK3β as a means to bolster dendritic cell functionality in the face of tumour-mediated immune suppression.

López González M, Oosterhoff D, Lindenberg JJ, Milenova I, Lougheed SM, Martiáñez T, Dekker H, Quixabeira DCA, Hangalapura B, Joore J, Piersma SR, Cervera-Carrascon V, Santos JM, Scheper RJ, Verheul HMW, Jiménez CR, Van De Ven R, Hemminki A, Van Beusechem VW, De Gruijl TD. López González M, et al. Oncoimmunology. 2019 Jul 19;8(10):e1631119. doi: 10.1080/2162402X.2019.1631119. eCollection 2019. Oncoimmunology. 2019. PMID: 31646076 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

37 results

Search Page

Filters